tbuckley/cabot-search huggingface dataset:
Single Cell RNA-Seq Characterization of an Adaptive Population of NK Cells after Primary CMV Infection in Rhesus Macaques
Authors: Stefan Cordes, Ryland D Mortlock, Lauren Truitt, Di Yang, Diego A Espinoza, Xing Fan, Daniel Ram, Matilda Mostrom, Dollnovan Tran, Lesli Sprehe, R. Keith Reeves, Robert E. Donahue, Michael Kelly, Jinguo Chen, So Gun Hong, Amitinder Kaur, Chuanfeng Wu, Cynthia E. Dunbar
Journal: Blood (2021)
Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Authors: Premal H. Thaker, Liz Y. Han, Aparna A. Kamat, Jesusa M. Arevalo, Rie Takahashi, Chunhua Lu, Nicholas B. Jennings, Guillermo Armaiz-Pena, James A. Bankson, Murali Ravoori, William M. Merritt, Yvonne G. Lin, Lingegowda S. Mangala, Tae Jin Kim, Robert L. Coleman, Charles N. Landen, Yang Li, Edward Felix, Angela M. Sanguino, Robert A. Newman, Mary Lloyd, David M. Gershenson, Vikas Kundra, Gabriel Lopez-Berestein, Susan K. Lutgendorf, Steven W. Cole, Anil K. Sood
Journal: Nature Medicine (2021)
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma
Authors: Andrew M. Evens, Kristina S. Yu, Nicholas Liu, Andy Surinach, Katie Holmes, Carlos Flores, Supriya Kumar, Michelle A. Fanale, Darcy R. Flora, Susan K. Parsons
Journal: Blood (2021)
Covid-19 Infection in Hematological Malignancies: Registry Data from India
Authors: Arihant Jain, Lingaraj Nayak, Uday Prakash Kulkarni, Nikita Mehra, Uday Yanamandra, Smita Kayal, Sharat Damodar, Joseph M John, Suvir Singh, Prashant Mehta, Pritesh Munot, Sushil Selvarajan, Venkatraman Radhakrishnan, Rajan Kapoor, Biswajit Dubashi, Bharath Ram S, Hasmukh Jain, Jayachandran PK, Jeyaseelan Lakshmanan, Thenmozhi Mani, Om Prakash, Jayashree Thorat, Satyaranjan Das, Biju George, Deepesh Lad, Pankaj Malhotra
Journal: Blood (2021)
Abstract 9559: Clinical Outcomes and Predictors of All-Cause Mortality After Complex High-risk and Indicated Revascularization Using Percutaneous Coronary Intervention
Authors: Akinori Satake, Yasuhiro Uchida
Journal: Circulation (2021)

Introduction: The concept of complex and high-risk indicated procedures using percutaneous coronary intervention (CHIP-PCI) has recently been defined. However, few studies have investigated the prognosis of patients after CHIP-PCI. Methods: CHIP-PCI was defined as a procedure satisfying at least one criterion each for both patient and procedure characteristics, as follows: patient characteristics [age (≥ 75 years old), low left ventricular ejection fraction (LVEF), diabetes mellitus, acute coronary syndrome, previous coronary artery bypass surgery, peripheral arterial disease, severe chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and severe valvular disease] and procedure characteristics [unprotected left main disease, degenerated saphenous or radial artery grafts, severely calcified lesions, last patent conduit, chronic total occlusions, multivessel disease, and use of mechanical circulatory support]. Between January 2017 and December 2018, we performed PCI for 695 consecutive patients in our hospital. Of these patients, CHIP-PCI was performed for 322 consecutive patients. Results: The survival rate was significantly lower in CHIP-PCI group than non-CHIP-PCI group (log-rank P &lt; 0.01, Figure). Moreover, on Cox multivariate hazard analysis, age (≥ 75 years old) (hazard ratio: 4.01, 95% confidence interval: 1.92-8.38, p &lt; 0.01), COPD (hazard ratio: 2.95, 95% confidence interval: 1.38-6.32, p &lt; 0.01), low LVEF (hazard ratio: 3.35, 95% confidence interval: 1.55-7.22, p &lt; 0.01), severe CKD (hazard ratio: 3.02, 95% confidence interval: 1.44-6.36, p &lt; 0.01), and use of mechanical circulatory support (hazard ratio: 5.97, 95% confidence interval: 2.72-13.10, p &lt; 0.01) remained significant predictors of mortality after CHIP-PCI.. Conclusions: The presence of advanced age, COPD, low LVEF, severe CKD, and mechanical circulatory support use might lead to worse clinical outcomes after CHIP-PCI.
Abstract 9523: Substituting Deep Learning Chest X-Ray Age for Chronological Age in the Pooled Cohort Equations
Authors: Vineet K Raghu, jakob weiss, Kaavya Paruchuri, Pradeep Natarajan, Hugo Aerts, Udo Hoffmann, Michael T Lu
Journal: Circulation (2021)

Introduction: Statin eligibility for primary prevention is based on the Pooled Cohort Equations (PCE) 10-year atherosclerotic cardiovascular disease risk calculator. A critical risk factor in the PCE is chronological age; a proxy for age-dependent arterial injury and atherosclerosis. We previously showed that deep learning can estimate a chest x-ray age (CXR-Age) from a chest radiograph image that is associated with cardiovascular mortality and may better measure vascular aging. Hypothesis: To test whether substituting an externally-derived CXR-Age for chronological age in the PCE improves prediction of incident major adverse cardiovascular events (MACE). Methods: Retrospective study of statin-naive patients (50-75 years old), who had a CXR, no prior MACE or diabetes, and low-density lipoprotein &lt;190 mg/dl. PCE risk was calculated using 1) chronological age 2) CXR-Age substituted for chronological age. The primary outcome was MACE (fatal/nonfatal myocardial infarction and stroke). Accuracy of MACE risk estimates using the PCE based on CXR-Age versus chronological age was compared using Harrel’s c-index and Net Reclassification Improvement. Hazard ratios between statin eligible (PCE ≥ 7.5%) and ineligible individuals were calculated using cox regression. Results: In 1,277 patients (mean age 61.0±6.8 years, 43.7% male), 118 (9.2%) MACE occurred over median 6.7 years of follow-up. Harrell’s c-index for the PCE using CXR-Age was higher than the PCE using chronological age (0.61 vs. 0.56; p=0.02). Those statin-eligible by the PCE using CXR-Age had higher hazard ratios for MACE than those eligible using chronological age (HR 2.68 [95% CI 1.76-4.08] vs. HR 1.50 [95% CI 1.05-2.16]; p=0.008). Net Reclassification Improvement using CXR-Age instead of chronological was 0.13 (95% CI 0.04-0.22). Conclusions: Substituting a deep learning-based CXR-Age for chronological age in the PCE improves risk prediction in a primary prevention setting.
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Authors: Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortes, Jean‐Charles Soria, Giuseppe Curigliano
Journal: CA A Cancer Journal for Clinicians (2021)

Abstract As distinct cancer biomarkers have been discovered in recent years, a need to reclassify tumors by more than their histology has been proposed, and therapies are now tailored to treat cancers based on specific molecular aberrations and immunologic markers. In fact, multiple histology‐agnostic therapies are currently adopted in clinical practice for treating patients regardless of their tumor site of origin. In parallel with this new model for drug development, in the past few years, several novel antibody–drug conjugates (ADCs) have been approved to treat solid tumors, benefiting from engineering improvements in the conjugation process and the introduction of novel linkers and payloads. With the recognition that numerous surface targets are expressed across various cancer histologies, alongside the remarkable activity of modern ADCs, this drug class has been increasingly evaluated as suitable for a histology‐agnostic expansion of indication. For illustration, the anti‐HER2 ADC trastuzumab deruxtecan has demonstrated compelling activity in HER2‐overexpressing breast, gastric, colorectal, and lung cancer. Examples of additional novel and potentially histology‐agnostic ADC targets include trophoblast cell‐surface antigen 2 (Trop‐2) and nectin‐4, among others. In the current review article, the authors summarize the current approvals of ADCs by the US Food and Drug Administration focusing on solid tumors and discuss the challenges and opportunities posed by the multihistological expansion of ADCs.
Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial
Authors: Andrew H. Wei, Hartmut Döhner, Hamid Sayar, Farhad Ravandi, Pau Montesinos, Hervé Dombret, Dominik Selleslag, Kimmo Porkka, Jun Ho Jang, Barry Skikne, C.L. Beach, Yu (Olivia) Tian, Gail J. Roboz
Journal: Blood (2021)
Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective
Authors: Keith W. Pratz, Xinglei Chai, Jipan Xie, Lei Yin, Xiaoyu Nie, Melissa Montez, Erica Iantuono, Lisa Downs, Esprit Ma
Journal: Blood (2021)
<i>DDX41</i> Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic <i>DDX41</i>: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort
Authors: Talha Badar, Ahmad Nanaa, Rong He, Aref Al-Kali, David S. Viswanatha, Emily Godsey, Lisa Z. Sproat, Mohamed A. Kharfan-Dabaja, Mrinal M. Patnaik, Hassan B. Alkhateeb, Mark R. Litzow, James M. Foran
Journal: Blood (2021)
Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
Authors: Sreeram Ramagopalan, Alind Gupta, Paul Arora, Kristian Thorlund, Joshua Ray, Vivek Subbiah
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Evidence regarding real-world effectiveness of therapies for patients with advanced non–small cell lung cancer (NSCLC) whose tumors are resistant to platinum-based chemotherapy is lacking. <h3>Objective</h3> To compare the effectiveness of the immune checkpoint inhibitors atezolizumab (programmed cell death ligand 1 inhibitor) and nivolumab (programmed cell death 1 inhibitor) and the chemotherapy drug docetaxel in patients with advanced NSCLC resistant to platinum-based chemotherapy. <h3>Design, Setting, and Participants</h3> This comparative effectiveness study compared patients aged 18 years or older with advanced NSCLC who initiated atezolizumab, docetaxel, or nivolumab and who had previously been exposed to platinum-based chemotherapy using nationally representative real-world data from more than 280 US cancer clinics. Patients were followed-up from May 2011 to March 2020. Data analysis was performed between April and June 2021. Comparisons of interest were between atezolizumab vs docetaxel and atezolizumab vs nivolumab. <h3>Exposures</h3> Initiation of atezolizumab, nivolumab, or docetaxel monotherapy. <h3>Main Outcome and Measures</h3> The main outcome was overall survival (OS). <h3>Results</h3> A total of 3336 patients (mean [SD] age, 67.1 [9.49] years; 1820 [54.6%] men and 1516 [45.4%] women) were assessed in the main analysis, including 206 patients receiving atezolizumab, 500 receiving docetaxel, and 2630 receiving nivolumab. Patients receiving atezolizumab were older than those treated with docetaxel (mean age [SD], 68.3 [9.4] years vs 65.6 [9.5] years), and were more likely to have been treated in an academic setting (39 patients [18.9%]) than those receiving docetaxel (49 patients [9.8%]) and nivolumab (128 patients [4.9%]). After adjustment for baseline characteristics, atezolizumab was associated with a significantly longer OS compared with docetaxel (adjusted hazard ratio [aHR], 0.79; 95% CI, 0.64-0.97). No significant difference in OS was observed between atezolizumab and nivolumab (aHR, 1.07; 95% CI, 0.89-1.28). These findings were consistent across all patient subgroups tested, and robust to plausible deviations from random missingness for Eastern Cooperative Oncology Group performance status in real-world data (eg, the tipping point for loss of a significantly beneficial effect for atezolizumab vs docetaxel was achieved if patients in the docetaxel group missing baseline Eastern Cooperative Oncology Group performance status had a mean performance status of 1.43 higher than expected). <h3>Conclusions and Relevance</h3> In this comparative effectiveness study, atezolizumab was superior to docetaxel and matched nivolumab in prolonging OS in a real-world cohort of patients with advanced NSCLC who previously received platinum-based chemotherapy.
Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a
Authors: Robert F. Sidonio, Alexis A. Thompson, Flora Peyvandi, Canan Albayrak, Seoh Leng Yeoh, Joyce Lam, Caterina Maggiore, Werner Engl, Geoffrey Allen, Srilatha Tangada
Journal: Blood (2021)
Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Langerhans Cell Histiocytosis
Authors: James A. Whitlock, Birgit Geoerger, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave
Journal: Blood (2021)
Inquiry into maternity care at Nottingham trust to investigate if incidents were downgraded
Authors: Clare Dyer
Journal: BMJ (2021)

A new inquiry into maternity services at a major NHS teaching trust will investigate whether serious incidents that should have been reported nationally were instead recorded internally as lower harm occurrences, allowing the trust to avoid proper scrutiny over its poor record of care for mothers and babies.

Work has now begun on the independent thematic review of maternity cases at Nottingham University Hospitals NHS Trust, where at least 46 babies suffered permanent brain damage and 19 were stillborn between 2010 and 2019. …
Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk
Authors: Allan D. Sniderman, Ann Marie Navar, George Thanassoulis
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Pozelimab, a Human Monoclonal Antibody Against Complement Factor C5, Provided Inhibition of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
Authors: Jun-Ho Jang, Jonathan Weyne, Umesh Chaudhari, Olivier Harari, Jutta Miller, Bradley Dain, Karoline A Meagher, Merideth L Rodgers, Lorah Perlee, Lori Morton, David M Weinreich, George D. Yancopoulos, Morag Griffin
Journal: Blood (2021)
Evaluation of an Artificial Intelligence–Augmented Digital System for Histologic Classification of Colorectal Polyps
Authors: Mustafa Nasir-Moin, Arief A. Suriawinata, Bing Ren, Xiaoying Liu, Douglas J. Robertson, Srishti Bagchi, Naofumi Tomita, Jason W. Wei, Todd A. MacKenzie, Judy R. Rees, Saeed Hassanpour
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Colorectal polyps are common, and their histopathologic classification is used in the planning of follow-up surveillance. Substantial variation has been observed in pathologists' classification of colorectal polyps, and improved assessment by pathologists may be associated with reduced subsequent underuse and overuse of colonoscopy. <h3>Objective</h3> To compare standard microscopic assessment with an artificial intelligence (AI)–augmented digital system that annotates regions of interest within digitized polyp tissue and predicts polyp type using a deep learning model to assist pathologists in colorectal polyp classification. <h3>Design, Setting, and Participants</h3> In this diagnostic study conducted at a tertiary academic medical center and a community hospital in New Hampshire, 100 slides with colorectal polyp samples were read by 15 pathologists using a microscope and an AI-augmented digital system, with a washout period of at least 12 weeks between use of each modality. The study was conducted from February 10 to July 10, 2020. <h3>Main Outcomes and Measures</h3> Accuracy and time of evaluation were used to compare pathologists' performance when a microscope was used with their performance when the AI-augmented digital system was used. Outcomes were compared using paired<i>t</i>tests and mixed-effects models. <h3>Results</h3> In assessments of 100 slides with colorectal polyp specimens, use of the AI-augmented digital system significantly improved pathologists' classification accuracy compared with microscopic assessment from 73.9% (95% CI, 71.7%-76.2%) to 80.8% (95% CI, 78.8%-82.8%) (<i>P</i> &lt; .001). The overall difference in the evaluation time per slide between the digital system (mean, 21.7 seconds; 95% CI, 20.8-22.7 seconds) and microscopic examination (mean, 13.0 seconds; 95% CI, 12.4-13.5 seconds) was –8.8 seconds (95% CI, –9.8 to –7.7 seconds), but this difference decreased as pathologists became more familiar and experienced with the digital system; the difference between the time of evaluation on the last set of 20 slides for all pathologists when using the microscope and the digital system was 4.8 seconds (95% CI, 3.0-6.5 seconds). <h3>Conclusions and Relevance</h3> In this diagnostic study, an AI-augmented digital system significantly improved the accuracy of pathologic interpretation of colorectal polyps compared with microscopic assessment. If applied broadly to clinical practice, this tool may be associated with decreases in subsequent overuse and underuse of colonoscopy and thus with improved patient outcomes and reduced health care costs.
Cigarette Smoke or Cigarette Condensate Exposure Accelerates Growth of FLT3-ITD AML Models, Induces Oxidative Stress, and Alters DNA Methylation
Authors: Mary Figueroa, Megan R Rodriguez, Marcos Estecio, Yue Lu, Seyed Javad Moghaddam, Elias J. Jabbour, Marina Konopleva, Courtney D. DiNardo, Joya Chandra
Journal: Blood (2021)
A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction
Authors: Daniel S. Kim, Nhu Quyen Dau, Harry Peled
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RECOMMENDED PIPERACILLIN-TAZOBACTAM DOSING IN CRITICALLY ILL PATIENTS REQUIRING CONTINUOUS VENO-VENOUS HEMOFILTRATION ENHANCES GRAM-NEGATIVE COLONIZATION AND INFECTION AND MAY INDUCE RESISTANCE
Authors: L. Remels, M. Diltoer, P. M. Honore, R. Jacobs, E. De Waele, V. Van Gorp, D. N. Nguyen, J. De Regt, J. Troubleyn, H. Spapen
Journal: Intensive Care Medicine (2014)
Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy
Authors: Ben J. Samelson-Jones, Spencer K. Sullivan, John E.J. Rasko, Adam Giermasz, Lindsey A. George, Jonathan M. Ducore, Jerome M. Teitel, Catherine E. McGuinn, Amanda O'Brien, Ian Winburn, Lynne M Smith, Amit Chhabra, Jeremy Rupon
Journal: Blood (2021)
COVID-19 and Sickle Cell Disease in the Province of Quebec: Morbidity and Mortality Rates Derived from the Provincial Registry
Authors: Mathias Castonguay, Nawar Dakhallah, Marie-Laure Colaiacovo, Camille Jimenez-Cortes, Justin Desroches, Anne-Marie Claveau, Amer Yassine Hafsaoui, Amalia Souza, Pauline Tibout, Anne-Marie Vincent, Veronique Naessens, Josee Brossard, Sharon Abish, Raoul Santiago, Denis Soulieres, Vincent Laroche, Yves D. Pastore, Thai Hoa Tran, Stéphanie Forté
Journal: Blood (2021)
Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Authors: Anne Mea Spanjaart, Per Ljungman, Rafael De La Camara, Gloria Tridello, Valentín Ortiz-Maldonado, Alvaro Urbano-Ispizua, Pere Barba, Mi Kwon, Dolores Caballero, Pierre Sesques, Emmanuel Bachy, Roberta Di Blasi, Catherine Thieblemont, Friso Calkoen, Pim G.N.J. Mutsaers, Johan A. Maertens, Livia Giannoni, Emma Nicholson, Matthew P. Collin, Carlos Pinho Vaz, Elisabetta Metafuni, Joaquín Martínez-López, Fiona Dignan, Josep-Maria Ribera, Arnon Nagler, František Folber, Robin Sanderson, Adrian Bloor, Fabio Ciceri, Nina Knelange, Francis A. Ayuk, Nicolaus Kröger, Marie José Kersten, Stephan Mielke
Journal: Blood (2021)
Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)
Authors: Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, Briony Shaw, Michelle Poon, Erin Paul, Matthew Ku, Mark Wong, Ashley Beekman, Michael Krigstein, Pietro R Di Ciaccio, Joel Wight, Caitlin Coombes, Michael Gilbertson, Amanda Tey, Jake Shortt, Chandramouli Nagarajan, Maya Latimer, Dipti Talaulikar, Nada Hamad, Sumita Ratnasingam, Tara Cochrane, Eliza Hawkes, Chan Yoon Cheah, Stephen Opat, Gareth P Gregory
Journal: Blood (2021)
Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results
Authors: Amitkumar Mehta, Wael Harb, Claire Xu, Yuan Meng, Linda Lee, Vivian Yuan, Zhengyi Wang, Pengfei Song, Joan Huaqiong Shen, Ajay K Gopal
Journal: Blood (2021)
Cytomegalovirus and tuberculosis disease in children
Authors: Helena Rabie, Lisa Jane Frigati, Nokwasi Nkosi
Journal: The Lancet Global Health (2021)

The risk of progressing from Mycobacterium tuberculosis infection to tuberculosis disease depends on the age at the time since infection. There is a complex relationship between tuberculosis and other infectious diseases; infections potentially alter the balance between immune responses that contain tuberculosis and those that allow disease progression. Understanding these associations provides potential insights into tuberculosis pathogenesis, can be used to assess progression risk in people with tuberculosis infection, and provides opportunities to prevent tuberculosis disease.